Jyong Biotech Ltd. Ordinary Shares (MENS) quarterly balance sheet — complete assets, liabilities & equity history
| Total Current Assets | 206K | 206K | 200K | 200K | 1.84M |
| Cash & Short-Term Investments | 98K | 98K | 96K | 96K | 177K |
| Cash Only | 98K | 98K | 96K | 96K | 177K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - |
| Other Current Assets | 108K | 3K | 104K | 3K | 1.66M |
| Total Non-Current Assets | 6.16M | 6.16M | 6.24M | 6.24M | 6.41M |
| Property, Plant & Equipment | 3.19M | 3.19M | 3.34M | 3.34M | 3.54M |
| Fixed Asset Turnover | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 2.97M | 2.97M | 2.9M | 2.9M | 2.87M |
| Total Assets | 6.37M | 6.37M | 6.44M | 6.44M | 8.25M |
| Asset Turnover | - | - | - | - | - |
| Asset Growth % | -22.82% | - | - | - | - |
| Total Current Liabilities | 12.13M | 12.13M | 11.93M | 11.93M | 14.26M |
| Accounts Payable | 3K | 3K | 9K | 9K | 2K |
| Days Payables Outstanding | 4.76 | - | 13.21 | - | - |
| Short-Term Debt | 7.28M | 7.28M | 7.46M | 7.46M | 7.97M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.33M | 3.37M | 3.31M | 3.33M | 4.99M |
| Current Ratio | 0.02x | 0.02x | 0.02x | 0.02x | 0.13x |
| Quick Ratio | 0.02x | 0.02x | 0.02x | 0.02x | 0.13x |
| Cash Conversion Cycle | - | - | - | - | - |
| Total Non-Current Liabilities | 30.76M | 30.76M | 29.43M | 29.43M | 28.06M |
| Long-Term Debt | 10.68M | 10.68M | 9.67M | 9.67M | 8.52M |
| Capital Lease Obligations | 16K | 16K | 77K | 77K | 69K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 20.06M | 20.06M | 19.68M | 19.68M | 19.47M |
| Total Liabilities | 42.88M | 42.88M | 41.37M | 41.37M | 42.32M |
| Total Debt | 18.14M | 18.14M | 17.37M | 17.37M | 16.69M |
| Net Debt | 18.04M | 18.04M | 17.27M | 17.27M | 16.51M |
| Debt / Equity | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - |
| Interest Coverage | -0.00x | -1.89x | -0.00x | -2.15x | -4.91x |
| Total Equity | -36.52M | -36.52M | -34.93M | -34.93M | -34.07M |
| Equity Growth % | -7.18% | - | - | - | - |
| Book Value per Share | -510.28 | -510.28 | -488.02 | -488.02 | -476.10 |
| Total Shareholders' Equity | -36.52M | -36.52M | -34.93M | -34.93M | -34.07M |
| Common Stock | 1K | 1K | 1K | 1K | 1K |
| Retained Earnings | -33.08M | -33.08M | -31.39M | -31.39M | -30.06M |
| Treasury Stock | -16.37M | -16.37M | -16.37M | -16.37M | -16.37M |
| Accumulated OCI | 1.12M | 1.12M | 1.02M | 1.02M | 548K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |